|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HOMEZ |
Gene summary for HOMEZ |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HOMEZ | Gene ID | 57594 |
| Gene name | homeobox and leucine zipper encoding | |
| Gene Alias | KIAA1443 | |
| Cytomap | 14q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8IX15 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57594 | HOMEZ | LZE4T | Human | Esophagus | ESCC | 1.77e-03 | 1.84e-01 | 0.0811 |
| 57594 | HOMEZ | LZE8T | Human | Esophagus | ESCC | 9.94e-06 | 1.37e-01 | 0.067 |
| 57594 | HOMEZ | LZE20T | Human | Esophagus | ESCC | 2.36e-03 | 1.01e-01 | 0.0662 |
| 57594 | HOMEZ | LZE22T | Human | Esophagus | ESCC | 3.21e-03 | 2.04e-01 | 0.068 |
| 57594 | HOMEZ | LZE24T | Human | Esophagus | ESCC | 4.27e-17 | 4.26e-01 | 0.0596 |
| 57594 | HOMEZ | LZE21T | Human | Esophagus | ESCC | 5.36e-04 | 2.35e-01 | 0.0655 |
| 57594 | HOMEZ | LZE6T | Human | Esophagus | ESCC | 1.67e-02 | 1.21e-01 | 0.0845 |
| 57594 | HOMEZ | P1T-E | Human | Esophagus | ESCC | 3.08e-03 | 2.77e-01 | 0.0875 |
| 57594 | HOMEZ | P2T-E | Human | Esophagus | ESCC | 3.93e-11 | 1.78e-01 | 0.1177 |
| 57594 | HOMEZ | P4T-E | Human | Esophagus | ESCC | 1.44e-20 | 4.68e-01 | 0.1323 |
| 57594 | HOMEZ | P5T-E | Human | Esophagus | ESCC | 3.97e-19 | 3.49e-01 | 0.1327 |
| 57594 | HOMEZ | P8T-E | Human | Esophagus | ESCC | 2.14e-21 | 2.97e-01 | 0.0889 |
| 57594 | HOMEZ | P9T-E | Human | Esophagus | ESCC | 1.16e-11 | 2.90e-01 | 0.1131 |
| 57594 | HOMEZ | P10T-E | Human | Esophagus | ESCC | 1.02e-20 | 3.19e-01 | 0.116 |
| 57594 | HOMEZ | P11T-E | Human | Esophagus | ESCC | 1.79e-05 | 1.89e-01 | 0.1426 |
| 57594 | HOMEZ | P12T-E | Human | Esophagus | ESCC | 3.71e-49 | 8.84e-01 | 0.1122 |
| 57594 | HOMEZ | P15T-E | Human | Esophagus | ESCC | 9.07e-53 | 1.12e+00 | 0.1149 |
| 57594 | HOMEZ | P16T-E | Human | Esophagus | ESCC | 2.27e-05 | 1.14e-01 | 0.1153 |
| 57594 | HOMEZ | P17T-E | Human | Esophagus | ESCC | 1.62e-08 | 2.51e-01 | 0.1278 |
| 57594 | HOMEZ | P19T-E | Human | Esophagus | ESCC | 5.39e-03 | 3.27e-01 | 0.1662 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HOMEZ | SNV | Missense_Mutation | rs774260897 | c.778N>T | p.Arg260Trp | p.R260W | Q8IX15 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| HOMEZ | SNV | Missense_Mutation | rs778435299 | c.788C>T | p.Pro263Leu | p.P263L | Q8IX15 | protein_coding | tolerated(0.25) | benign(0.001) | TCGA-C8-A1HE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HOMEZ | SNV | Missense_Mutation | novel | c.1117T>A | p.Ser373Thr | p.S373T | Q8IX15 | protein_coding | deleterious(0.03) | benign(0.366) | TCGA-LL-A73Z-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| HOMEZ | deletion | Frame_Shift_Del | rs767665872 | c.1127delT | p.Leu376TyrfsTer14 | p.L376Yfs*14 | Q8IX15 | protein_coding | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| HOMEZ | SNV | Missense_Mutation | c.851N>T | p.Ser284Phe | p.S284F | Q8IX15 | protein_coding | deleterious(0.01) | benign(0.44) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HOMEZ | SNV | Missense_Mutation | c.320G>A | p.Arg107His | p.R107H | Q8IX15 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| HOMEZ | SNV | Missense_Mutation | rs781133712 | c.1144C>T | p.Arg382Trp | p.R382W | Q8IX15 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HOMEZ | SNV | Missense_Mutation | rs111256939 | c.434N>T | p.Ala145Val | p.A145V | Q8IX15 | protein_coding | tolerated_low_confidence(0.13) | benign(0.007) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| HOMEZ | SNV | Missense_Mutation | rs200450330 | c.1066C>T | p.Arg356Cys | p.R356C | Q8IX15 | protein_coding | deleterious(0) | possibly_damaging(0.446) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HOMEZ | SNV | Missense_Mutation | c.134N>A | p.Pro45His | p.P45H | Q8IX15 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |